Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b study of AMG 757 in neuroendocrine prostate cancer
NL-OMON58991Phase 1Completed
- Sponsor
- Amgen
- Start
- Sep 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of tarlatamab in neuroendocrine prostate cancer (NEPC), sponsored by Amgen. Primary endpoint: Primary endpoint(s). Started Sep 2021; status: completed.
02
Drugs
tarlatamab
03
Conditions
neuroendocrine prostate cancer (NEPC)
Beyond the preview
Go deeper on NL-OMON58991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58991.